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Background: Iron deficiency (ID) is frequent in heart failure (HF), linked with exercise intolerance and poor prognosis. Its correction with 
intravenous iron improves clinical status. Accurate diagnosis of ID is mandatory, but remains uncertain, as the definition of ID based on circulating 
iron biomarkers may be unreliable.
objectives: To assess the prevalence of ID in bone marrow in patients with ischemic systolic HF, to assign the iron biomarker with the best 
accuracy for the diagnosis of ID in bone marrow, to establish the prevalence of ID using this biomarker and its impact on survival in patients with 
systolic HF.
design, setting and participants: A case control study with iron staining in bone marrow in 30 patients with ischemic HF, and 10 healthy 
controls, and an observational study at 3 tertiary cardiology centers of 791patients with systolic HF. Main Outcome Measures: Bone marrow 
specimens were stained for iron, and ID was diagnosed for 0-1 grades according to Gale scale. Serum ferritin, iron, transferrin saturation (Tsat), 
soluble transferrin receptor (sTfR) were assessed as circulating iron biomarkers.
results: ID in bone marrow was found in 25 (83%) of patients with ischemic HF, and none of controls (p<0.001). Serum sTfR had the best accuracy 
in predicting ID in bone marrow (area under curve: 0.920±0.063, for cut-off of ≥1.25 mg/L - sensitivity: 67%, specificity: 100%). Serum sTfR ≥1.25 
mg/L was found in 47% of all patients with systolic HF, in 56% and 46% of anemics and non-anemics, respectively (p<0.05). The reclassification 
methods revealed that serum sTfR significantly added the prognostic value to the baseline prognostic model, and its additive prognostic value was 
greater than that of plasma NT-proBNP. Based on the internal derivation and validation procedures, serum sTfR ≥1.41±1.13 mg/L was established 
as the cut-off with the best accuracy in predicting death at 3-year follow-up.
conclusions: High serum sTfR accurately reflects depleted iron stores in bone marrow in patients with systolic HF, and allows to identify those of 
high mortality.
